U.S. Life Sciences Stock News

NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

Axsome Therapeutics (AXSM) Is Up 6.2% After Highlighting Key FDA Decision on Auvelity

Axsome Therapeutics recently highlighted the upcoming release of its first-quarter 2026 results on May 4 and the pending US Food and Drug Administration decision on Auvelity for agitation associated with Alzheimer's disease, a potential new indication for its central nervous system portfolio. Analysts see the Alzheimer's agitation application for Auvelity as a potentially meaningful new revenue stream, given the high unmet medical need and expectations that the drug may avoid an added...
NasdaqGM:RYTM
NasdaqGM:RYTMBiotechs

Is Rhythm Pharmaceuticals (RYTM) Still Attractive After A 48.9% One‑Year Share Price Gain

Wondering whether Rhythm Pharmaceuticals at US$86.13 still makes sense for your portfolio, or if the recent price leaves little margin for value? The stock has pulled back by 0.2% over the last week and 7.4% over the last month, while the 1‑year return sits at 48.9% and the 5‑year return at 315.3%. Recent coverage has focused on Rhythm Pharmaceuticals as a specialist in rare genetic disorders, with attention on how its approved therapy and commercial rollout are shaping expectations...
NYSE:CF
NYSE:CFChemicals

A Look At CF Industries (CF) Valuation After Ceasefire News Cools Fertilizer Supply Fears

CF Industries Holdings (CF) is back in focus after news of a U.S.–Iran ceasefire cooled expectations of prolonged fertilizer supply constraints, triggering a pullback that followed an earlier rally tied to Persian Gulf disruptions. See our latest analysis for CF Industries Holdings. The ceasefire headlines triggered a sharp reset in expectations, but CF Industries’ recent 46.88% 3 month share price return and 72.42% 1 year total shareholder return still point to strong momentum that has built...
NYSE:UPS
NYSE:UPSLogistics

Ceasefire Eases Fuel Costs And Reshapes The UPS Profit Story

A ceasefire in the Strait of Hormuz is allowing vessels to pass more freely, easing recent disruptions in oil flows. Crude oil prices have pulled back, reducing fuel costs for global shippers including United Parcel Service (NYSE:UPS). Lower fuel expenses improve UPS's operating environment and may support stronger profit margins versus the recent conflict period. For United Parcel Service, the shift in fuel costs comes at a time when the stock has shown mixed performance, with a 3.6% gain...
NYSE:CALX
NYSE:CALXCommunications

Does Calix’s Governance Stance and BBT Traction Shift the Bull Case for CALX?

In March 2026, Calix, Inc. filed a definitive proxy statement urging shareholders to vote against a proposal to replace supermajority voting thresholds with simple majority requirements in its charter and bylaws. Separately, broadband provider BBT reported strong year-over-year ARPU growth and rapid rollout of Calix-powered small business services, underlining tangible customer momentum for Calix’s platform. With BBT’s ARPU gains tied to Calix One and SmartBiz, we’ll examine how this...
NYSE:CAAP
NYSE:CAAPInfrastructure

Is It Too Late To Consider Corporación América Airports (NYSE:CAAP) After Its Multi‑Year Surge?

Wondering if Corporación América Airports at US$27.07 is priced for its future potential or already reflects the story you care about? This article focuses squarely on what you are paying versus what you might be getting. The stock has seen a 5.5% return over the last 7 days, 4.9% over the last month, 1.9% year to date, 56.0% over the last year and a very large gain over 3 and 5 years. This naturally raises questions about how much of that performance is already baked into the current...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

Does New Epidiolex Behavioral Data at AAN 2026 Reframe Jazz Pharmaceuticals’ (JAZZ) Neuroscience Strategy?

Jazz Pharmaceuticals recently announced it will present six abstracts, including one oral presentation, at the 2026 American Academy of Neurology Annual Meeting, sharing new clinical data on Epidiolex for rare epilepsies and Xywav for narcolepsy. A key update is the 6‑month EpiCom analysis showing reduced caregiver‑ and clinician‑reported behavioral problems in patients with tuberous sclerosis complex–associated seizures after starting Epidiolex, underlining the drug’s potential impact...
NYSE:DOCN
NYSE:DOCNIT

Is It Too Late To Consider DigitalOcean Holdings (DOCN) After Its 173.5% One Year Rally?

Wondering whether DigitalOcean Holdings at around US$75.59 is still priced for opportunity or already reflects the story you are buying into today? This article walks through the numbers so you can judge how the current price lines up with the underlying business. The stock has seen a 16.0% decline over the last 7 days, a 10.0% gain over 30 days, is up 54.4% year to date and has returned 173.5% over the past year, which can change how risk and reward feel at today's level. Recent coverage...
NYSE:HEI
NYSE:HEIAerospace & Defense

HEICO Expands Aerospace And Defense Reach With Earnings Accretive Acquisitions

HEICO (NYSE:HEI) has agreed for its Flight Support Group to acquire 80% of Sherwood Avionics and Accessories. HEICO’s Electronic Technologies Group has agreed to acquire 90% of Southwest Antennas, a supplier of rugged RF and microwave antennas. Both transactions are expected to be immediately accretive to earnings and to expand HEICO’s reach in aerospace repair, defense and communications solutions. For investors following NYSE:HEI, these transactions add fresh detail to how the company...
NYSE:TALO
NYSE:TALOOil and Gas

Talos Energy (TALO) Is Down 7.2% After Iran Ceasefire Pressures Oil Prices Has The Bull Case Changed?

In recent days, Talos Energy has faced shifting sentiment after a U.S.-Iran ceasefire, the reopening of the Strait of Hormuz, and talk of sanctions relief altered expectations for global oil supply and pressured crude prices. This development highlights how quickly geopolitical moves can change the operating backdrop for offshore producers that rely heavily on stable, supportive commodity markets. We’ll now explore how the prospect of increased Iranian supply and softer crude prices could...
NasdaqGS:NEOG
NasdaqGS:NEOGMedical Equipment

Neogen (NEOG) Q3 Losses Keep Margin Concerns Central To Bullish Discount Narrative

Neogen (NEOG) has just posted Q3 2026 results with revenue of US$211.2 million and a basic EPS loss of US$0.08, alongside trailing twelve month revenue of US$870.6 million and a basic EPS loss of US$2.80. This keeps the focus firmly on how efficiently the business is converting sales into earnings. Over recent quarters the company has seen revenue move from US$231.3 million in Q2 2025 to US$225.5 million in Q4 2025, then to US$209.2 million in Q1 2026 and US$224.7 million in Q2 2026 before...
NasdaqGS:MRVL
NasdaqGS:MRVLSemiconductor

Assessing Marvell Technology (MRVL) Valuation After Strong Recent Share Price Momentum

Why Marvell Technology Has Drawn Fresh Investor Attention Marvell Technology (MRVL) has been drawing attention after a strong recent run in its shares, with the stock up 4.8% over the past week and 32.6% over the past month. Over the past 3 months, Marvell shares have returned 44.1%, while the 1 year total return stands at 125.2%. That move has pushed the company’s market value to about US$104.9b at the latest close of US$119.93. See our latest analysis for Marvell Technology. The recent 1...
NYSE:GE
NYSE:GEAerospace & Defense

Is GE (GE) Turning Governance Scrutiny Into a Strategic Advantage for Its Aerospace Story?

On March 30, 2026, JLens and the Anti-Defamation League urged GE Aerospace shareholders to vote against a proposal criticizing the company’s defense business and its product sales to the Israel Defense Forces, arguing it could harm operations and mischaracterizes the role of the U.S. government in foreign military sales. The dispute highlights how rising scrutiny of defense supply chains and human rights due diligence is increasingly shaping governance debates around large aerospace...
NasdaqGS:AMAT
NasdaqGS:AMATSemiconductor

Assessing Applied Materials (AMAT) Valuation After New AI Chip Deposition Systems Lift Market Confidence

Why Applied Materials’ new AI chip tools matter for shareholders Applied Materials (AMAT) recently launched two deposition systems for 2nm Gate All Around AI chips, and the stock quickly moved higher as investors focused on what this could mean for future demand. The tools target atomic scale manufacturing issues that affect chip speed and power use, and they are already being adopted by major foundries. This adoption places Applied Materials in the middle of ongoing AI infrastructure...
NasdaqGS:CALM
NasdaqGS:CALMFood

How CALM’s Q3 Earnings Slide and M&A Push May Be Recasting Its Capital Allocation Story

In the third quarter of fiscal 2026, Cal-Maine Foods reported sharply lower sales of US$666.95 million and net income of US$50.46 million year-on-year, announced a variable cash dividend of about US$0.36 per share, outlined active acquisition plans, and added Dudley D. Wooley to its Board of Directors. Beyond the earnings drop, management’s focus on selective M&A across conventional, specialty, prepared foods and ingredients suggests a widening multi-segment egg platform aimed at reinforcing...
NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

A Look At Recursion Pharmaceuticals (RXRX) Valuation As Investor Narratives Diverge On Future Potential

Stock performance snapshot Recursion Pharmaceuticals (RXRX) has drawn investor attention after recent trading left the shares around US$3.28, with mixed performance over the past week, month and past 3 months. The stock shows a 0.8% decline over 1 day, a 5.6% gain over 7 days, a 4.8% decline over the past month and a 29.5% decline over the past 3 months, alongside a 21.8% decline year to date. See our latest analysis for Recursion Pharmaceuticals. Despite the recent 7 day share price return...
NYSE:KD
NYSE:KDIT

Is Kyndryl (KD) Using AI-Powered Workplace Automation To Offset Rising Legal And Governance Concerns?

In early April 2026, Kyndryl launched its AI-powered Digital Twin for the Workplace, built on Microsoft Foundry and Azure to proactively detect and resolve employee technology issues using predictive intelligence, automation and operational insight. This new capability, alongside the recently introduced Agentic Service Management framework, highlights Kyndryl's push into production-grade, autonomous IT service operations while it faces multiple securities class action lawsuits alleging false...
NYSE:OC
NYSE:OCBuilding

Owens Corning (OC) Valuation Check After Recent Share Price Rebound

Owens Corning stock at a glance after recent performance Owens Corning (OC) has seen mixed share performance recently, with the stock down about 0.6% on the day but higher over the past week and month, while the past 3 months and year show declines. See our latest analysis for Owens Corning. At a share price of $114.28, Owens Corning’s 7-day and 30-day share price returns of 7.97% and 6.48% contrast with its 1-year total shareholder return decline of 15.75% and a more moderate total return of...
NasdaqGS:STRL
NasdaqGS:STRLConstruction

Sterling Infrastructure (STRL) Valuation Check As Sustainability Report And CEC Acquisition Draw Fresh Attention

Sustainability report and acquisition move Sterling into focus Sterling Infrastructure (STRL) is back on investors' radar after releasing its 2026 Sustainability Report and closing the CEC Facilities Group acquisition, which tightens the link between infrastructure growth, cash generation, and ESG commitments. See our latest analysis for Sterling Infrastructure. The share price has been strong, with a 44.86% 90 day share price return and 39.85% year to date share price return, while the 1...
NasdaqGS:AXON
NasdaqGS:AXONAerospace & Defense

Axon Enterprise (AXON) Valuation Check After Sharp Multi Period Share Price Pullback

Recent performance snapshot Axon Enterprise (AXON) has pulled back recently, with the share price down around 1.5% over the past day, 16% over the past week, and roughly one third over the past month. Over the past 3 months, the stock has declined about 45%. The year-to-date move is roughly 39% lower, leaving the 1-year total return also about 39% in the red. See our latest analysis for Axon Enterprise. The recent drop in Axon Enterprise's share price, with the current level around $345.94,...
NYSE:WHD
NYSE:WHDEnergy Services

Is Cactus (WHD) Board Reshuffle Quietly Reframing Its Margin-Driven Investment Narrative?

Cactus, Inc. announced that director Bruce Rothstein informed the company he would not stand for re-election at the 2026 Annual Meeting, prompting the board to reduce its size to eight members effective immediately before that meeting. The orderly board reshaping, with no disagreements cited over operations or policies, highlights Cactus’s emphasis on continuity in governance while it executes its broader growth plans. With this orderly board transition underway, we’ll explore how Cactus’s...
NYSE:TNL
NYSE:TNLHospitality

A Look At Travel + Leisure (TNL) Valuation After Iran Ceasefire Eases Geopolitical Tensions

Geopolitical pause and Travel + Leisure's latest share move A temporary suspension of military activity in Iran, announced by President Trump, eased recent geopolitical tensions and coincided with Travel + Leisure (TNL) shares climbing about 5%, as travel and vacation names reacted to expectations of lower energy prices. See our latest analysis for Travel + Leisure. With the latest move taking the share price to US$75.82, Travel + Leisure has a 7 day share price return of 6.41% and a year to...
NYSE:ABBV
NYSE:ABBVBiotechs

How AbbVie’s Dermatology Data Push and Humira Discount Strategy Will Impact AbbVie (ABBV) Investors

In late March 2026, AbbVie highlighted extensive new clinical data across its dermatology portfolio at the American Academy of Dermatology meeting, including long-term outcomes for Skyrizi and Rinvoq and investigational results in vitiligo and alopecia areata, underscoring its focus on immune-mediated skin diseases and quality-of-life measures. Around the same time, AbbVie also moved to broaden access and tighten pricing frameworks by launching Humira at a steep discount on the TrumpRx...
NYSE:CW
NYSE:CWAerospace & Defense

Is It Too Late To Consider Curtiss Wright (CW) After Its 1 Year Surge?

Wondering whether Curtiss-Wright at around US$725.71 is priced for perfection or still offers value? This article focuses squarely on what that share price implies. The stock has recent returns of 4.4% over 7 days, 4.8% over 30 days, 26.8% year to date and 129.6% over 1 year, with a 3 year return of 317.8% and a 5 year return of 488.9%. This raises fair questions about how much of the story is already in the price. Recent coverage has focused on Curtiss-Wright's role in aerospace and...